Clinical Trials Browser

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT04759248 2025-09-09

ATREZZO

Phase 2 Active not recruiting

55 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT06031233 2025-05-21

MINUTE

Phase 4 Recruiting

679 enrolled

Tumor-Agnostic

Neoplasms

NCT05912062 2023-09-29

BiOnHER

Unknown

80 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

300 enrolled

Tumor-Agnostic

Neoplasms

NCT01985893 2016-01-14

THOR

Phase 2 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01235897 2014-04-17

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

Phase 1 Completed

17 enrolled 7 charts

Tumor-Agnostic

Neoplasms

NCT00440622 2013-02-13

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Phase 3 Terminated

90 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT00453635 2012-03-13

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Phase 2 Terminated

88 enrolled

Breast

Breast Neoplasms, Neoplasms

Clinical Trials

TAPUR

I-SPY

H3RAKLES

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

DETERMINE

DETERMINE

ATREZZO

ProTarget

MINUTE

BiOnHER

Efficacy and Safety of Precision Therapy in Refractory Tumor

THOR

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients